Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression

NCT: NCT04448327 · COMPLETED

NCT IDNCT04448327
StatusCOMPLETED
Start Date2021-01-29
Completion2025-06-14

Brief Summary

This study will identify the sex-dependent impact of expiratory-gated transcutaneous vagus nerve stimulation (tVNS) on the modulation of the stress response circuitry and associated physiology in major depressive disorder (MDD). We will evaluate a sample of 80 adults with recurrent MDD randomized to receive active or sham expiratory-gated tVNS during a functional magnetic resonance imaging (fMRI) session, with simultaneous mood and physiological assessments. We hypothesize that expiratory-gated tVNS will effectively modulate, in a sex-dependent manner, specific brainstem-cortical pathways of the stress circuitry and attenuate physiological deficits in MDD.

Frequently Asked Questions

What is Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression?

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression is a clinical trial registered under NCT04448327. Current status: COMPLETED.

What is the status of NCT04448327?

The current status of NCT04448327 (Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression) is: COMPLETED.

When did Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression start?

Impact of Transcutaneous Vagal Nerve Stimulation on Stress Response in Major Depression started on 2021-01-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.